Crossmark

Efficacy of fulvestrant and capecitabine as maintenance therapy in patients with HR +/HER2 − metastatic breast cancer benefited from first-line chemotherapy

Crossref DOI link: https://doi.org/10.1007/s00210-025-04717-4

Published Online: 2025-12-16

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Qing

Yu, Lingyan

Zeng, Zhiwen

Li, Zhangyun
License Information

Text and Data Mining valid from 2025-12-16

Version of Record valid from 2025-12-16
More Information

Article History

Received: 20 May 2025

Accepted: 3 October 2025

First Online: 16 December 2025

Declarations

:

: The study was approved by the Ethics Committee of the Third Hospital of Nanchang City (Approval No. K-ky2022005); all experiments were performed in accordance with relevant guidelines and regulations, such as the Declaration of Helsinki, and the patients signed the informed consent form and agreed to be published.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below